RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals Inc. today reported positive interim results from an ongoing Phase 2 study of VT-1161, the Company’s novel oral antifungal compound, in patients with moderate-to-severe interdigital tinea pedis (ITP), also known as athlete’s foot. This study is intended as a precursor to a Phase 2b study in patients with onychomycosis, a very common fungal infection of the nail. VT-1161 is an inhibitor of the fungal enzyme CYP51, the target of the current triazole antifungals, but is from a novel chemical class that was rationally designed by Viamet with the goal of providing a superior efficacy profile and avoiding many of the side effects that characterize these current triazole antifungal agents.
Help employers find you! Check out all the jobs and post your resume.
